SMARCA4 and adenocarcinoma: The data from the Atlas database are consistent with Sanger sequencing studies of BRG1 in lung cancer, where abrogating BRG1 mutations (squamous and adenocarcinoma) are relatively low at 0.56 and 3.31% of tumors, while the loss of BRG1 expression occurred in ~15–30% (6, 19, 76, 101).